Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 24;5(23):4864–4876. doi: 10.1182/bloodadvances.2020003737

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

PMC Copyright notice

Figure 5. — RARA SE presence predicts pAML in vivo sensitivity to tamibarotene. (A) Effect of tamibarotene (6 mg/kg by oral gavage daily) on peripheral blood leukemic burden in p401, a RARA SE+ pAML PDX mice (n = 5 per arm). (B) Effect of tamibarotene treatment on the liver and spleen weights of p401 PDX mice at time of euthanasia. (C) Effect of tamibarotene treatment on survival of p401 PDX mice. (D) CD38⁺ cells percentage in response to tamibarotene treatment in p401 PDX mice. (E) Effect of tamibarotene on the peripheral blood leukemia burden of p198, an RARA SE− pAML PDX (n = 6 per arm). (F) Effect of tamibarotene treatment on the liver and spleen weights of p198 PDX mice at time of euthanasia. (G) Effect of tamibarotene treatment on survival of p198 PDX mice. (H) Body weights of both p401 and p198 mice treated with tamibarotene over time. **.001 < P < .01; ***.0001 < P< .001. n.s., not significant.